Stoke Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Stoke Therapeutics (STOK).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$41Upside to Avg. PT+57.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2026	JP Morgan	Jessica Fye	Reinstates	Overweight	$40
Aug 4, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$60
Aug 4, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$38→$40
Aug 4, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$60→$58
Aug 4, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$35
Jul 13, 2026	Goldman Sachs	Kevin Strang	Initiate	Buy	$44
May 11, 2026	BTIG	Thomas Shrader	Maintained	Buy	$39
Mar 20, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$36→$60
Mar 19, 2026	BTIG	Thomas Shrader	Maintained	Buy	$39
Mar 18, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$36→$38
Mar 18, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$35
Mar 17, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$36→$38
Mar 17, 2026	Needham	Joseph Stringer	PT Raise	Buy	$35→$40
Feb 24, 2026	Wolfe Research	Rudy Li	Initiate	Outperform	$40
Jan 12, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$32→$36
Jan 5, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$24→$35
Jan 5, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$28→$36
Dec 15, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$35→$50
Nov 5, 2025	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$24→$28
Nov 5, 2025	Wedbush	Laura Chico	PT Raise	Outperform	$22→$32

Analyst Ratings News

PRO
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $60 to $58.

Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.

Benzinga Newsdesk

Stoke Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Stoke Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

PRO
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

PRO
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

PRO
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

PRO
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

PRO
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

People Also Watch

People Also Watch

Stoke Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Stoke Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

PROGuggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

PROWedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

PROCanaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

PROGoldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

PROBTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

People Also Watch

People Also Watch

PRO
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

PRO
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

PRO
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

PRO
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

PRO
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

PRO
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target